Sildenafil Stops Progressive Chamber, Cellular, and Molecular Remodeling and Improves Calcium Handling and Function in Hearts With Pre-Existing Advanced Hypertrophy Caused by Pressure Overload

被引:122
作者
Nagayama, Takahiro [1 ]
Hsu, Steven [1 ]
Zhang, Manling [1 ]
Koitabashi, Norimichi [1 ]
Bedja, Djahida [2 ]
Gabrielson, Kathleen L. [2 ]
Takimoto, Eiki [1 ]
Kass, David A. [1 ]
机构
[1] Johns Hopkins Med Inst, Div Cardiol, Dept Med, Baltimore, MD 21205 USA
[2] Johns Hopkins Med Inst, Dept Comparat Med & Comparat Pathol, Baltimore, MD 21205 USA
关键词
PDE5; pressure overload; hypertrophy; myocyte; cardiac function; RAT CARDIAC MYOCYTES; NITRIC-OXIDE; PROTEIN-KINASE; PHOSPHODIESTERASE-5; INHIBITION; NATRIURETIC-PEPTIDE; FAILURE; CONTRACTILITY; CYCLASE; CARDIOMYOPATHY; CALCINEURIN;
D O I
10.1016/j.jacc.2008.08.069
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective This study sought to test the efficacy of phosphodiesterase type 5A (PDE5A) inhibition for treating advanced hypertrophy/remodeling caused by pressure overload, and to elucidate cellular and molecular mechanisms for this response. Background Sildenafil (SIL) inhibits cyclic guanosine monophosphate-specific PDE5A and can blunt the evolution of cardiac hypertrophy and dysfunction in mice subjected to pressure overload. Whether and how it ameliorates more established advanced disease and dysfunction is unknown. Methods Mice were subjected to transverse aortic constriction (TAC) for 3 weeks to establish hypertrophy/dilation, and subsequently treated with SIL (100 mg/kg/day) or placebo for 6 weeks of additional TAC. Results The SIL arrested further progressive chamber dilation, dysfunction, fibrosis, and molecular remodeling, increasing myocardial protein kinase G activity. Isolated myocytes from TAC-SIL hearts showed greater sarcomere shortening and relaxation, and enhanced Ca2+ transients and decay compared with nontreated TAC hearts. The SIL treatment restored gene and protein expression of sarcoplasmic reticulum Ca2+ uptake adenosine triphosphatase (SERCA2a), phospholamban (PLB), and increased PLB phosphorylation (S16), consistent with improved calcium handling. The phosphatase calcineurin (Cn) and/or protein kinase C-alpha (PKC alpha) can both lower phosphorylated phospholamban and depress myocyte calcium cycling. The Cn expression and PKC alpha activation (outer membrane translocation) were enhanced by chronic TAC and reduced by SIL treatment. Expression of PKC delta and PKC epsilon also increased with TAC but were unaltered by SIL treatment. Conclusions SIL treatment applied to well-established hypertrophic cardiac disease can prevent further cardiac and myocyte dysfunction and progressive remodeling. This is associated with improved calcium cycling, and reduction of Cn and PKC alpha activation may be important to this improvement. (J Am Coll Cardiol 2009; 53: 207-15) (C) 2009 by the American College of Cardiology Foundation
引用
收藏
页码:207 / 215
页数:9
相关论文
共 34 条
[1]   Cardiovascular protection using beta-blockers - A critical review of the evidence [J].
Bangalore, Sripal ;
Messerli, Franz H. ;
Kostis, John B. ;
Pepine, Carl J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (07) :563-572
[2]   Sildenafil inhibits β-adrenergic-stimulated cardiac contractility in humans [J].
Borlaug, BA ;
Melenovsky, V ;
Marhin, T ;
Fitzgerald, P ;
Kass, DA .
CIRCULATION, 2005, 112 (17) :2642-2649
[3]   PKC-α regulates cardiac contractility and propensity toward heart failure [J].
Braz, JC ;
Gregory, K ;
Pathak, A ;
Zhao, W ;
Sahin, B ;
Klevitsky, R ;
Kimball, TF ;
Lorenz, JN ;
Nairn, AC ;
Liggett, SB ;
Bodi, I ;
Wang, S ;
Schwartz, A ;
Lakatta, EG ;
DePaoli-Roach, AA ;
Robbins, J ;
Hewett, TE ;
Bibb, JA ;
Westfall, MV ;
Kranias, EG ;
Molkentin, JD .
NATURE MEDICINE, 2004, 10 (03) :248-254
[4]   β-adrenoceptor blocker treatment and the cardiac β-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure [J].
Brodde, Otto-Erich .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2007, 374 (5-6) :361-372
[5]   Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes [J].
Castro, LRV ;
Verde, I ;
Cooper, DMF ;
Fischmeister, R .
CIRCULATION, 2006, 113 (18) :2221-2228
[6]   Prognostic significance of left ventricular mass change during treatment of hypertension [J].
Devereux, RB ;
Wachtell, K ;
Gerdts, E ;
Boman, K ;
Nieminen, MS ;
Papademetriou, V ;
Rokkedal, J ;
Harris, K ;
Aurup, P ;
Dahlöf, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (19) :2350-2356
[7]   Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes [J].
El-Armouche, Ali ;
Bednorz, Anna ;
Pamminger, Torsten ;
Ditz, Diana ;
Didie, Michael ;
Dobrev, Dobromir ;
Eschenhagen, Thomas .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 346 (03) :700-706
[8]   Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity [J].
Fisher, PW ;
Salloum, F ;
Das, A ;
Hyder, H ;
Kukreja, RC .
CIRCULATION, 2005, 111 (13) :1601-1610
[9]   Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart [J].
Forfia, Paul R. ;
Lee, Myung ;
Tunin, Richard S. ;
Mahmud, Mobusher ;
Champion, Hunter C. ;
Kass, David A. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (10) :1079-1088
[10]   Long-term use of sildenafil in the therapeutic management of heart failure [J].
Guazzi, Marco ;
Samaja, Michele ;
Arena, Ross ;
Vicenzi, Marco ;
Guazzi, Maurizio D. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (22) :2136-2144